Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P02787

UPID:
TRFE_HUMAN

ALTERNATIVE NAMES:
Beta-1 metal-binding globulin; Siderophilin

ALTERNATIVE UPACC:
P02787; O43890; Q1HBA5; Q9NQB8; Q9UHV0

BACKGROUND:
Serotransferrin, identified by its alternative names Beta-1 metal-binding globulin and Siderophilin, is essential for iron transport in the body. It binds iron ions in conjunction with an anion, facilitating their transport to sites of need. Beyond its primary role in iron metabolism, serotransferrin is implicated in cell proliferation and serves as an iron source for certain microbial infections, highlighting its complex role in both human physiology and microbial pathogenesis.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Serotransferrin could open doors to potential therapeutic strategies. Its direct involvement in Atransferrinemia, a disorder marked by iron overload and anemia due to transferrin synthesis abnormalities, presents a unique opportunity for developing treatments that can modulate transferrin levels and activity, offering hope for patients suffering from this rare condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.